The insertion in P{EP}GLazEP2383 is 1.5kb upstream of GLaz.
GLazEP2383 induction, under the control of Scer\GAL4da.G32 results in greater resistance to hyperoxia.
GLazEP2383 induction, under the control of Scer\GAL4da.G32 leads to an increase in mean lifespan at 29oC of 18%.
Expression of GLazEP2383, under the control of Scer\GAL4D42, Scer\GAL4Act5C or Scer\GAL4elav-C155 at 29oC does not have any beneficial effect on lifespan, although expression under the control of Scer\GAL4hs.PB gives a notable lifespan extension (21% increase over wild-type).
Expression of GLazEP2383 in the central nervous system and some muscles, under the control of Scer\GAL412.1 at 29oC results in an 18% increase in lifespan.
Expression of GLazEP2383 in the central nervous system and some muscles, under the control of Scer\GAL4109(2)80 at 29oC results in an 29% increase in lifespan.
Expression of GLazEP2383 in the fat and some muscles, under the control of Scer\GAL4Lk6-DJ634 at 29oC results in an 17% increase in lifespan.
Expression of GLazEP2383 in the fat and some muscles, under the control of Scer\GAL4how-24B at 29oC results in an 10% increase in lifespan.
Expression of GLazEP2383 in the eye and salivary glands, under the control of Scer\GAL4GMR.PF at 29oC results in an 22% increase in lifespan.